BioSpace News Archive

As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

The novel immunomodulatory therapy Bempegaldesleukin developed by Nektar Therapeutics (NKTR) has demonstrated clear and durable improvement in patient response in frontline metastatic melanoma in combination with nivolumab.

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced an agreement with PT Etana Biotechnologies Indonesia (Etana) to out-license BYVASDA®

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2021.

The NIH’s National Institute on Aging announced on January 15 that a cornucopia of research grants is now offered to probe infectious possibilities in the causation of Alzheimer’s.

The study will be conducted in the Clinical Research Center of the University of Chicago under the leadership of Dr. Alexandra Dumitrescu, the Principal Investigator.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that it has received CE Mark for its Diamondback 360® Coronary Orbital Atherectomy System (OAS) and ViperWire Advance® Coronary Guide Wire with Flex Tip

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole

ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Mary Reilly as Chief Operating Officer (COO).